The Global Lung Cancer Drug Market was valued at USD 29 Billion in 2023 and is projected to reach a market size of USD 57.97 Billion by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 10.4%.
Lung cancer is the second-most common cancer, the treatments of which were not possible in previous times. Further, this resulted in an increase in mortality rates. Additionally, there were limited treatment options such as chemotherapy, however, it too caused certain side effects to patients. Furthermore, recent advancements in technology increased the efficiency of therapies and introduced new-age treatments such as targeted therapy, combination therapies for improving the quality of life, and other forms of treatments. Furthermore, the future holds positive for the lung cancer drug market with the rise in demand for personalized medicines and treatments.
Key Market Insights:
As per WHO (World Health Organization), smoking is the major cause of lung cancer and about 85% of lung cancer cases are attributed to smoking.
Further, according to the American Cancer Society, about 80%-85% of lung cancers are non-small cell lung cancer (NSCLC) and 10%-15% of lung cancers are small cell lung cancer (SCLC)
As per the Indian Council of Medical Research, India will witness a seven-fold increase in lung cancer cases by the year 2025. Further, as per their study, the number will go above 1.61 lakh in the year 2025, with approximately 81,000 plus cases among males and 30,000 among females.
Lung Cancer Drug Market Drivers:
The rising prevalence of lung cancer has contributed to the growth of the lung cancer drug market.
Lung cancers have been increasing at an alarming rate, which is further leading to deaths. Usually, smokers are prone to lung cancers and as per the American Cancer Society, about 8 out of 10 cancer deaths are due to smoking. However, it was also found that even non-smokers were diagnosed with lung cancer. Further, one of the major contributing reasons for lung cancer is the fast-aging population, especially in the Asia-Pacific region, followed by the North American region. Older people are more prone to chronic diseases such as lung cancer, and hence there is an increase in demand for lung cancer drugs in the market. Moreover, the median age of lung cancer diagnosis, as per the National Institutes of Health is 70 years and about 68% of patients are already diagnosed with lung cancer after 65 years of age. Further, this has led to an increase in demand for early screening and detection of lung cancer by patients.
Rising issues of lung cancer due to extreme environmental & working conditions have boosted the market demand for lung cancer drugs.
Recent years witnessed rising environmental concerns, which affected both human and animal health. Moreover, air pollution has become a prime reason contributing to lung cancer in individuals. Further, pollutants released from air-polluting materials such as particulate matter, which are also known as carcinogens contribute to lung diseases in people. According to the National Institutes of Health, outdoor pollution caused about 108,000 deaths due to lung cancer. In addition to that, environmental concerns at the workplace affect workers’ health adversely. These include laborers working in factories and manufacturing units exposed to harsh chemical fumes, asbestos, radioactive elements, and various other emissions that eventually affect their respiratory systems. Moreover, one of the major lung cancer diseases among occupational workers is pneumoconiosis – known as black lung disease, which is caused when exposed to coal dust and particles. All these reasons have necessitated the need for efficient lung cancer drugs in the market.
Lung Cancer Drug Market Restraints & Challenges:
Potential side effects to some individuals due to drug delivery in the body can hamper the market potential of lung cancer drugs.
Pharmaceutical drugs undergo various phases of clinical trials before they are marketed. However, even after successful clinical testing, many drugs cause potential side effects to the patients, as sometimes it does not suit their bodies or conflict with other health issues in their bodies such as diabetes or during pregnancy. This can eventually deter patients from continuing the treatment process and hence hinder the growth opportunities for lung cancer drugs in the market.
Regulatory issues can affect the production and distribution of lung cancer drugs in the market.
The pharmaceutical industry is exposed to various concerns related to regulatory, clinical, and legal, which slow down their trial processes and ultimately affect their production in the market. Moreover, stringent regulations by the government and drug approval organizations delay the treatment process and therefore affect the market demand for lung cancer drugs.
Lung Cancer Drug Market Opportunities:
The lung cancer drug market can benefit through technological advancements in the healthcare sector. These include computational biomarkers, AI drug-monitoring devices, and telemedicine. Further, companies seeking market potential can research and manufacture in these areas and expand their market reach. Further, novels in genetic testing and therapeutics for lung cancer such as RNA-based therapies and targeted gene therapies are other areas that contribute to the further development of the lung cancer drug market.
LUNG CANCER DRUG MARKET REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2023 - 2030 |
|
Base Year |
2023 |
|
Forecast Period |
2024 - 2030 |
|
CAGR |
10.4% |
|
Segments Covered |
By Cancer Type, Treatment, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regional Scope |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Key Companies Profiled |
AstraZeneca, Novartis, Pfizer, GlaxoSmithKline (GSK), Merck, Amgen, Sanofi, Takeda, Roche, Bristol Myers Squibb |
Non-Small Cell Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Mesothelioma
Others
Based on market segmentation by cancer type, NSCLC occupied the highest share of about 28% in the year 2023 in the market. Non-small cell lung cancer is the most common and major type of lung cancer suffered by patients. Further, the most common sub-type of NSCLC is lung adenocarcinoma, which is mostly found in the outer part of the lungs. Moreover, it is caused due to various factors, however, the most common factor contributing to the growth of this cancer is gene dysregulation, that is, the accumulation of mutations in various genes, resulting in uncontrolled proliferation of the lung cells. This further leads to the development of tumors. Therefore, there is an increasing demand for targeted lung cancer drugs and therapies in the market. Furthermore, chemotherapy is the most common type of treatment used to treat lung cancer cases, as it destroys the cancer cells and prevents them from further spreading in the body. Furthermore, specialized treatments lead to improvement in the survival rates of lung cancer patients. As per the American Cancer Society, NSCLC has a 5 years survival rate of about 28% as compared to other types of cancer.
Small cell lung cancer (SCLC) occupied the second position in the year 2023 in the market. SCLC, though accounts for 10%-15% of all types of cancer, is more aggressive in nature and has comparatively less survival rates than others. Therefore, it requires immediate treatment strategies to reduce the cancer cell growth. Furthermore, the incidences of SCLC are less than NSCLC, however, is faster in growth. Moreover, the elderly population aged between 60-80 years of age are prone to this type of cancer. Additionally, smokers are more likely to develop SCLC and as per a study in Medline, nearly 98% of people suffering from this disease have a history of smoking. This has necessitated the need for effective and speedy treatment of this type of cancer due to its aggressive nature. Further, targeted therapies are being developed for SCLC, which can quickly reduce its growth in other parts of the body. Additionally, chemotherapy is another widely used treatment for treating SCLC in patients with limited-stage disease.
Chemotherapy
Targeted Therapy
Immunotherapy
Anti-Angiogenesis Drugs
Combination Therapies
PARP Inhibitors
Others
Based on market segmentation by treatment, chemotherapy occupied the highest share of about 25% in the year 2023 in the market. Chemotherapy is the most common type of treatment for inhibiting the growth of cancer cells. It is often used in the primary stage of the treatment or combination with other types of therapies. Furthermore, platinum-based chemotherapies such as cisplatin and carboplatin are widely used to treat NSCLC. Moreover, chemotherapy offers numerous benefits to lung cancer patients, which include shrinking the tumors and reducing the recurrence of cancer in the body. Furthermore, doctors recommend using this therapy in SCLC and the early stages of NSCLC.
The targeted therapy segment occupied second position in the year 2023 in the market. The growth of targeted therapy or precision medicines has increased, as a result of the rising demand for personalized treatments. Moreover, in these therapies, a specific molecule is targeted inside the lungs to shrink cancer and prevent its growth. Additionally, these therapies help in analyzing the development of lung cancer due to genetic mutation and thus aid in devising appropriate drug and treatment strategies. Further, some of the most widely used drugs for treating lung cancer in targeted therapy are EGFR inhibitors, ALK inhibitors, ROS1 inhibitors, and others. Furthermore, advancements in the genetic field have contributed to the development and demand for genetic mutation-targeting drugs for treating lung cancer in patients.
North America
Europe
Asia-Pacific
South America
The Middle East & Africa
Based on market segmentation by region, Europe occupied the highest share of about 28% in the year 2023 in the market. Having well-established healthcare facilities and the presence of various market leaders in the European pharmaceutical industry is a key factor contributing to the growth of lung cancer drugs in the market. Furthermore, the high prevalence of lung cancer due to high smoking rates has necessitated the need for innovative lung cancer treatment in the region. For instance, according to the World Health Organization, the European region has the highest prevalence of smoking tobacco with about 28% of adults. Moreover, Hungary, a country in Europe has recorded the highest rate of lung cancer globally in the year 2020, of about 50.1 incidence rate per 100,000 people. (World Cancer Research Fund International). Furthermore, chemotherapy is widely used to treat lung cancer in the region and innovations in immunotherapies are taking place to boost the survival rates of patients in the region.
The fastest-growing segment is Asia-Pacific during the forecast period. Due to the prevalence of the aging population and high number of smokers in countries such as China, Japan, and India, there is an increase in demand for lung cancer drugs in the Asia-Pacific market. Furthermore, radiotherapy combined with chemotherapy is widely used in countries such as India, for treating lung cancer patients.
COVID-19 Impact Analysis on the Lung Cancer Drug Market:
The pandemic had a mixed impact on the lung cancer drug market. Due to the shifted focus towards treating virus-infected patients, there was a delay in the diagnosis and treatment of lung cancer in patients. However, this was offset by the rise of telemedicine during the pandemic, thus availing remote consultations for patients with healthcare professionals. Moreover, supply chain disruptions affected the drug distribution and manufacturing process leading to a decline in the overall productivity of lung cancer drugs. In addition, the healthcare resource allocation such as monetary and research resources were directed towards the pandemic, which adversely affected the lung cancer drug manufacturing companies and declined their growth in the market.
Latest Trends/ Developments:
The lung cancer drug market is witnessing drastic developments in the market as a result of an increase in demand for personalized medicines and treatments, such as biomarker therapies, biosimilars, and others are in continuous development for treating NSCLC and SCLC in patients. Further, trends in liquid biopsy such as detecting lung cancer cells post-surgery and disease monitoring are further shaping the market potential for lung cancer drugs. Moreover, clinical trials and the development of pediatric drugs for reducing the risk of lung cancer are further boosting the growth of lung cancer in the market. These include Eflornithine (Iwilfin) (approved in December 2023), Bosutinib (Bosulif) (approved in September 2023), and others
Key Players:
AstraZeneca
Novartis
Pfizer
GlaxoSmithKline (GSK)
Merck
Amgen
Sanofi
Takeda
Roche
Bristol Myers Squibb
In October 2023, Bristol Myers Squibb acquired Mirati Therapeutics to gain access to FDA-approved non-small cell lung cancer (NSCLC) drugs Krazati, which is a best-in-class KRAS G12C inhibitor. Moreover, this acquisition aimed to diversify the product portfolio of Bristol Myers Squibb in the market.
In March 2021, Pfizer received approval from US FDA for its lung cancer drug – LORBRENA. The drug is meant for adults with metastatic non-small cell lung cancer, whose tumors are ALK-positive as detected by the FDA-approved test.
Global automotive lighting refers to all vehicle lighting systems, from headlamps that illuminate the road to taillights that communicate movements. They guarantee motorists and other road users alike safety, visibility, and style. While taillights frequently use LEDs for improved visibility, headlights are available in a variety of technologies, including LED and laser. Interior illumination, DRLs, and signal lights all have a role to play. This market, which was estimated to be worth $33.64 billion in 2022, is anticipated to rise to $67.39 billion by 2030 because of laws, luxury tastes, safety concerns, and technological developments like OLED taillights and adaptive headlights. Anticipate a future dominated by intelligent, connected, personalized, and sustainable lighting systems that enhance the safety, efficiency, and aesthetic appeal of automobiles.
Car lighting works its magic to provide safety, visibility, and style. Headlights cut through the night, taillights express intent, and interiors shine with comfort. The billion-dollar global business is expected to rise due to consumer demand for high-end experiences, safer roads, and cutting-edge technology. Imagine dynamic messages being painted by taillights, headlights that adjust to the road, and interiors that customize their atmosphere. Driven by technological advancements like linked systems and laser beams, this future is calling. Anticipate even more visually attractive, environmentally friendly, and intelligent lighting to illuminate the way ahead, making cars safer, more efficient, and unquestionably cooler.
In the market for automobile lighting, safety is the driving force behind demand from the public and laws. While automated high beams smoothly react to traffic, adaptive headlights modify their beams so as not to blind other people. With visually striking displays, dynamic taillights convey intentions for braking and turning. Beyond these developments, integrated pedestrian identification and lane departure alerts will soon make roads safer and brighter for everyone.
Luxurious automobile lighting creates a distinct visual identity that goes beyond simple illumination. Personalized interior lighting customizes the driving experience by setting the mood with a range of colours and intensities, while intricate designs and distinctive DRLs modify exteriors. As you approach your automobile at night, welcoming lights lead the way, resulting in an interior that is perfectly lit. Not only is this symphony of light aesthetically pleasing, but it also stands as a tribute to luxury. Upcoming developments like gesture-controlled lighting and holographic displays promise to further enhance the experience.
The worldwide automotive lighting market is undergoing a significant transition towards energy-efficient solutions, as environmental concerns gain prominence. LED technology is leading the way, providing a ray of hope for the environment and drivers alike. LED lights beam brighter and use a lot less energy than conventional halogen lamps. There are some tangible advantages to this. For drivers, this translates to increased fuel economy, which lowers petrol prices and lessens reliance on fossil fuels. Greater air quality and a reduction in the transport sector's contribution to climate change are the results of reduced overall emissions.
Although the global automotive lighting business is booming, there are still unknowns. Difficulties impede growth even as innovation propels it with eye catching features like laser beams and adaptable headlights. These technologies are luxury items due to their high cost and difficult integration, which puts producers' abilities to the test. The worldwide patchwork created by unclear legislation limits the potential of innovation. Durability issues persist, particularly when complex systems are subjected to challenging conditions. Ultimately, a lot of drivers still don't fully understand how these improvements can help them. Together, we can overcome these obstacles. The keys to reducing costs are improved production, more seamless integration, and unified regulations. Their full potential can be realized by educating customers about the safety, efficiency, and aesthetic value of these lighting wonders. By working together, we can pave the way for an even brighter and safer future for vehicle lighting.
It is made possible by advanced LED technology, which gives drivers the ability to customize their illumination for the highest level of comfort and flair. Consumers that care about the environment want greener products, and vehicle lighting complies. While solar- and self-powered lighting technologies offer a future powered by clean energy, energy-efficient LEDs lower pollution. The advent of connected lighting systems heralds a new age. Envision automobiles interacting with infrastructure and one another to minimize accidents and enhance traffic efficiency. Integrated headlights with pedestrian recognition provide unmatched safety, while dramatic taillights with eye-catching displays alert onlookers to your intentions. The possibilities are endless in the future. Gesture-controlled interior illumination, holographic displays projected onto the road, and even light fixtures with self-healing capabilities.
Due to laws requiring safety features like headlights, taillights, and brake lights, exterior lighting presently holds the most market share in the vehicle lighting industry. The dominance of this market is partly attributed to advancements in safety-focused technologies such as adaptive headlights and daytime running lights. The market value of external lighting is increased by the quick adoption of technology like LED bulbs and laser lights, which improve performance and aesthetics. Conversely, the interior lighting market is expected to increase at the fastest rate in the upcoming years. Innovations like ambient lighting and technology breakthroughs like LED and OLED displays, driven by consumer demand for comfort and personalisation, open new possibilities. The spread of sophisticated interior lighting systems is further driven by the growing emphasis on safety and the expansion of the luxury car market.
The worldwide vehicle lighting market is currently dominated by halogen because of its more affordable price, advanced technology, and useful illumination. With its dependable supply chain and affordable option for manufacturers and cost-conscious customers, halogen holds the biggest market share. The fastest-growing market right now is LEDs, which are predicted to shortly overtake halogen. The rapid expansion of LEDs is driven by their higher efficiency, longer lifespan, flexibility in design, and technological breakthroughs including enhanced brightness. Because LEDs use less energy and produce fewer emissions and better fuel economy, they are becoming more and more popular in the changing automotive lighting market.
Passenger automobiles rule the worldwide automotive lighting market. The sheer number of passenger cars produced which surpasses that of business vehicles and fuels the need for lighting systems is the primary cause of this popularity. The growing demand for personal automobiles in developing nations is a result of rising disposable income, which in turn drives the rise of the passenger car market. The importance that consumers place on safety and aesthetics elements helps to drive market expansion. But in the upcoming years, the market for electric and hybrid cars is expected to develop at the quickest rate. The exponential rise of the worldwide electric car market, which is still expanding and shows no signs of slowing down, is what is driving this surge. Specialised lighting solutions are required since electric and hybrid vehicles have different lighting requirements because of their specific functionality and design aesthetics.
Most lighting systems sold nowadays are sold by OEMs (Original Equipment Manufacturers), primarily because manufacturers pre-install lighting systems in new cars. But in the next years, the aftermarket is expected to develop at the quickest rate. This spike in demand for replacement parts, especially lighting systems, can be linked to several variables, one of them being the average age of cars. The industry is expanding because of consumers' growing desire to personalise their cars with aftermarket lighting upgrades such LED upgrades and decorative lighting. The availability and affordability of technologies like adaptive headlights and laser lights in the aftermarket, together with other advancements in lighting technology, are driving demand even more. Moreover, the growing market for electric cars (EVs).
Throughout the forecast period, Asia Pacific is anticipated to be the automotive lighting market with the highest profitability. Over the past few years, Asia Pacific countries like China and India have seen notable increases in automotive manufacturing and sales, primarily in the medium-to premium luxury car segment. Asia Pacific is predicted to see an increase in the manufacturing of passenger cars, with India experiencing the strongest growth rate. Depending on the state of the national economy, the area offers a suitable selection of both high-end and cheap cars. For instance, there is a substantial demand for halogen, Xenon/HID, and LED since China and India produce more economy and mid-range automobiles. On the other hand, luxury car adoption rates are greater in South Korea and Japan, where LED lighting is the norm.
A brief shadow was thrown by COVID-19 over the worldwide automotive lighting market. Production was stopped by lockdowns and supply chain disruptions, while luxury lighting upgrades were shelved by consumers on a tight budget. Resources became scarce, and R&D stagnated. Still, the market is recovering thanks to resurgent demand and rearranged priorities. While energy-efficient LEDs are being pushed towards adoption by sustainability, safety concerns are driving interest in features like pedestrian detection and adaptive headlights. The digital push of the epidemic creates opportunities for intelligent, networked lighting systems that may interact with infrastructure and other cars. Ultimately, the industry is positioned to shine brighter, focused on safety, sustainability, and a connected future, even though the pandemic dimmed its brilliance.
A development collaboration between OSRAM Continental and REHAU aims to incorporate lighting into external components, providing automobile manufacturers with innovative lighting options that improve functionality and design flexibility. For rear combination lamps, Hella unveiled a revolutionary lighting innovation called Hella FlatLight technology. A Memorandum of Understanding (MoU) was signed by Samvardhana Motherson Automotive Systems Group BV (SMRPBV), a division of Motherson Group, and Marelli Automotive Lighting to investigate a technology collaboration focused on intelligently lighted external body components. Valeo debuted their revolutionary 360° lighting system at the Shanghai Auto Show. This technology surrounds the car with a band of light, projecting instantaneous, clear signs that other drivers can see from a distance. Pedestrians, cyclists, and scooter riders are especially susceptible to these signals
The Global Lung Cancer Drug Market was valued at USD 29 Billion in 2023 and is projected to reach a market size of USD 57.97 Billion by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 10.4%.
The rising prevalence of lung cancer and Rising issues of lung cancer due to extreme environmental & working conditions are the drivers of the Lung Cancer Drug market.
Based on cancer type, the Global Lung Cancer Drug Market is segmented into Non-Small Cell Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Mesothelioma, and Others.
Europe is the most dominant region for the Global Lung Cancer Drug Market.
AstraZeneca, Novartis, Pfizer, GlaxoSmithKline, and Merck are the key players operating in the Global Lung Cancer Drug Market.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Specify your preferred Countries, Segments, or timeframes
Unlock Country Level Outlook, Trends, Cross-country Comparability, or supply Chain Variations.
Analyst Support
Every order comes with Analyst Support.
Customization
We offer customization to cater your needs to fullest.
Verified Analysis
We value integrity, quality and authenticity the most.
